The University of Southampton
University of Southampton Institutional Repository

Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin

Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin
Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin

Sandhoff disease is a neurodegenerative disorder resulting from the autosomal recessive inheritance of mutations in the HEXB gene, which encodes the β-subunit of β-hexosaminidase. G(M2) ganglioside fails to be degraded and accumulates within lysosomes in cells of the periphery and the central nervous system (CNS). There are currently no therapies for the glycosphingolipid lysosomal storage diseases that involve CNS pathology, including the G(M2) gangliosidoses. One strategy for treating this and related diseases is substrate deprivation. This would utilize an inhibitor of glycosphingolipid biosynthesis to balance synthesis with the impaired rate of catabolism, thus preventing storage. One such inhibitor is N- butyldeoxynojirimycin, which currently is in clinical trials for the potential treatment of type 1 Gaucher disease, a related disease that involves glycosphingolipid storage in peripheral tissues, but not in the CNS. In this study, we have evaluated whether this drug also could be applied to the treatment of diseases with CNS storage and pathology. We therefore have treated a mouse model of Sandhoff disease with the inhibitor N- butyldeoxynojirimycin. The treated mice have delayed symptom onset, reduced storage in the brain and peripheral tissues, and increased life expectancy. Substrate deprivation therefore offers a potentially general therapy for this family of lysosomal storage diseases, including those with CNS disease.

0027-8424
6388-6393
Jeyakumar, Mylvaganam
2afcb1bb-c6ff-4f74-9f75-5e1a4fd271c0
Butters, Terry D.
891552e5-fab9-49f8-9e0a-7fccb5920e35
Cortina-Borja, Mario
028ebae2-003d-413b-95cc-47d76914b006
Hunnam, Victoria
011d5184-08a6-4d9d-8b21-b00ae840bc25
Proia, Richard L.
c1c20347-9813-462b-8fe2-111b430c429a
Perry, V. Hugh
8f29d36a-8e1f-4082-8700-09483bbaeae4
Dwek, Raymond A.
5fb1a0ce-1ac6-4825-8ff0-f62c7164ff0c
Platt, Frances M.
3b0d9f95-fba8-4083-91e2-c567c3e77582
Jeyakumar, Mylvaganam
2afcb1bb-c6ff-4f74-9f75-5e1a4fd271c0
Butters, Terry D.
891552e5-fab9-49f8-9e0a-7fccb5920e35
Cortina-Borja, Mario
028ebae2-003d-413b-95cc-47d76914b006
Hunnam, Victoria
011d5184-08a6-4d9d-8b21-b00ae840bc25
Proia, Richard L.
c1c20347-9813-462b-8fe2-111b430c429a
Perry, V. Hugh
8f29d36a-8e1f-4082-8700-09483bbaeae4
Dwek, Raymond A.
5fb1a0ce-1ac6-4825-8ff0-f62c7164ff0c
Platt, Frances M.
3b0d9f95-fba8-4083-91e2-c567c3e77582

Jeyakumar, Mylvaganam, Butters, Terry D., Cortina-Borja, Mario, Hunnam, Victoria, Proia, Richard L., Perry, V. Hugh, Dwek, Raymond A. and Platt, Frances M. (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proceedings of the National Academy of Sciences of the United States of America, 96 (11), 6388-6393. (doi:10.1073/pnas.96.11.6388).

Record type: Article

Abstract

Sandhoff disease is a neurodegenerative disorder resulting from the autosomal recessive inheritance of mutations in the HEXB gene, which encodes the β-subunit of β-hexosaminidase. G(M2) ganglioside fails to be degraded and accumulates within lysosomes in cells of the periphery and the central nervous system (CNS). There are currently no therapies for the glycosphingolipid lysosomal storage diseases that involve CNS pathology, including the G(M2) gangliosidoses. One strategy for treating this and related diseases is substrate deprivation. This would utilize an inhibitor of glycosphingolipid biosynthesis to balance synthesis with the impaired rate of catabolism, thus preventing storage. One such inhibitor is N- butyldeoxynojirimycin, which currently is in clinical trials for the potential treatment of type 1 Gaucher disease, a related disease that involves glycosphingolipid storage in peripheral tissues, but not in the CNS. In this study, we have evaluated whether this drug also could be applied to the treatment of diseases with CNS storage and pathology. We therefore have treated a mouse model of Sandhoff disease with the inhibitor N- butyldeoxynojirimycin. The treated mice have delayed symptom onset, reduced storage in the brain and peripheral tissues, and increased life expectancy. Substrate deprivation therefore offers a potentially general therapy for this family of lysosomal storage diseases, including those with CNS disease.

This record has no associated files available for download.

More information

Accepted/In Press date: 9 March 1999
e-pub ahead of print date: 25 May 1999
Published date: 25 May 1999

Identifiers

Local EPrints ID: 489648
URI: http://eprints.soton.ac.uk/id/eprint/489648
ISSN: 0027-8424
PURE UUID: 29243ff3-2d7f-4a74-aa6b-1d36966bb061

Catalogue record

Date deposited: 30 Apr 2024 16:41
Last modified: 30 Apr 2024 16:41

Export record

Altmetrics

Contributors

Author: Mylvaganam Jeyakumar
Author: Terry D. Butters
Author: Mario Cortina-Borja
Author: Victoria Hunnam
Author: Richard L. Proia
Author: V. Hugh Perry
Author: Raymond A. Dwek
Author: Frances M. Platt

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×